Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Binding mode of the peptide YY carboxyterminus to the human Y2 receptor

Bo Xu, Silvana Vasile, Soren Ostergaard, Johan F. Paulsson, Jasna Pruner, Johan Aqvist, Birgitte S. Wulff, Hugo Gutierrez-de-Teran and Dan Larhammar
Molecular Pharmacology January 24, 2018, mol.117.110627; DOI: https://doi.org/10.1124/mol.117.110627
Bo Xu
1 Department of Nauropharmacology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvana Vasile
2 Department of Cell and Molecular Biology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soren Ostergaard
3 Peptide and Protein Chemistry, Novo Nordisk A/S;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan F. Paulsson
4 Oberity Research, Novo Nordisk A/S;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasna Pruner
1 Department of Nauropharmacology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Aqvist
2 Department of Cell and Molecular Biology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgitte S. Wulff
4 Oberity Research, Novo Nordisk A/S;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugo Gutierrez-de-Teran
5 Uppsala University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Larhammar
1 Department of Nauropharmacology, Uppsala University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Understanding the agonist-receptor interactions in the neuropeptide Y (NPY)/peptide YY (PYY) signaling system is fundamental for the design of novel modulators of appetite regulation. We report here a binding model for the native peptide agonist PYY to the human Y2 receptor based on computational and in vitro pharmacological analyses. The Molecular Dynamics (MD) simulations yielded a conserved binding orientation for the full PYY and five analogues truncated at the amino terminus, which were pharmacologically characterized. The subsequent mutagenesis studies focused on the area binding the common NPY/PYY C-terminal fragment, 32TRQRY36-amide. Several combinations of receptor mutants and PYY-(3-36) analogues modified at either of residues T32, Q34 and the amide group, were designed and tested in binding assays. The results were interpreted by means of MD and Free Energy Perturbation (FEP) simulations of selected mutants. Our results provide a detailed map of the interactions of the PYY/NPY C-terminal fragment with the transmembrane cavity of the Y2 receptor, which can be used as a basis for optimization of Y2 receptor agonists.

  • G protein-coupled receptors (GPCRs)
  • Molecular modeling
  • Neuropeptides
  • Obesity
  • Site-directed mutagenesis
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 102 (2)
Molecular Pharmacology
Vol. 102, Issue 2
1 Aug 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Binding mode of the peptide YY carboxyterminus to the human Y2 receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Binding mode of the peptide YY carboxyterminus to the human Y2 receptor

Bo Xu, Silvana Vasile, Soren Ostergaard, Johan F. Paulsson, Jasna Pruner, Johan Aqvist, Birgitte S. Wulff, Hugo Gutierrez-de-Teran and Dan Larhammar
Molecular Pharmacology January 24, 2018, mol.117.110627; DOI: https://doi.org/10.1124/mol.117.110627

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Binding mode of the peptide YY carboxyterminus to the human Y2 receptor

Bo Xu, Silvana Vasile, Soren Ostergaard, Johan F. Paulsson, Jasna Pruner, Johan Aqvist, Birgitte S. Wulff, Hugo Gutierrez-de-Teran and Dan Larhammar
Molecular Pharmacology January 24, 2018, mol.117.110627; DOI: https://doi.org/10.1124/mol.117.110627
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-aromatase activity of exemestane phase II metabolites
  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics